President Donald Trump on Sept. 13 announced his signing of an executive order on drug pricing.
The latest step would replace a July 24 Trump executive order.
It extends the mandate to prescription drugs available at a pharmacy, which are covered under Medicare Part D. The July version focused on drugs typically administered in doctors’ offices and health clinics, covered by Medicare Part B.
Specifically, it would pay a price for a drug that matches the lowest price paid among wealthy foreign governments. Medicare, the government healthcare program for seniors, is currently prohibited from negotiating prices it pays to drugmakers.
The president has made it a campaign point that he will take on big pharmaceutical companies, rejecting advertising campaigns from drug companies amid his efforts to lower prices.
The order will force drug companies to give Americans the best prices on pharmaceuticals.
Trump has often called for lowering the cost of prescription drugs. Congress hasn’t yet passed a major drug price reform measure.
At the time, he also gave a one-month deadline for drugmakers to propose alternative plans to reduce drug prices, adding that his administration would place a cap on U.S. drug prices if he’s not satisfied.
These orders also come just weeks before the November election and at a time when pharmaceutical firms are vying to create a vaccine for the virus, commonly called the novel coronavirus. Drug companies including AstraZeneca, Pfizer, Novavax, and Moderna are performing clinical trials on possible vaccines.
The orders received swift pushback from the pharmaceutical industry. Pharmaceutical Research and Manufacturers of America said in a statement that the move was “a reckless distraction that impedes our ability to respond to the current pandemic—and those we could face in the future.”
